The Dialysis Access Consortium (DAC) is an NIDDK-funded multi-center consortium that was developed to investigate interventions to improve hemodialysis vascular access outcomes in patients with end-stage renal disease (ESRD). The goals of the consortium are to identify effective therapies that will reduce the rate of graft and fistula failure in hemodialysis patients through a series of randomized, controlled, clinical trials over a five year period.